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Abstract 1 
Objective 2 
Dietary supplementation with fermentable carbohydrate protects against body weight gain. 3 
Fermentation by the resident gut microbiota produces short-chain fatty acids, which act at 4 
free fatty acid receptor 2 (FFAR2). Our aim was to test the hypothesis that FFAR2 is 5 
important in regulating the beneficial effects of fermentable carbohydrate on body weight 6 
and to understand the role of gut hormones PYY and GLP-1.  7 
Methods 8 
Wild-type or Ffar2-/- mice were fed an inulin supplemented or control diet. Mice were 9 
metabolically characterized and gut hormone concentrations, enteroendocrine cell density 10 
measurements were carried out. Intestinal organoids and colonic cultures were utilized to 11 
substantiate the in vivo findings.   12 
Results 13 
We provide new mechanistic insight into how fermentable carbohydrate regulates 14 
metabolism. Using mice that lack FFAR2, we demonstrate that the fermentable 15 
carbohydrate inulin acts via this receptor to drive an 87% increase in the density of cells that 16 
produce the appetite-supressing hormone peptide YY (PYY), reduce food intake, and 17 
prevent diet-induced obesity.  18 
Conclusion  19 
Our results demonstrate that FFAR2 is predominantly involved in regulating the effects of 20 
fermentable carbohydrate on metabolism and does so, in part, by enhancing PYY cell 21 
density and release. This highlights the potential for targeting enteroendocrine cell 22 
differentiation to treat obesity.  23 
 24 
Key words: Obesity, Diet, Peptide YY, Microbiota, Colon.  25 
 26 
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1. Introduction 1 
Obesity is currently one of the most serious global threats to human health and an important 2 
modifiable risk factor for type-2 diabetes, hypertension, and certain cancers [1-3]. 3 
Susceptibility to obesity is determined by genetic background, diet, and lifestyle. Additionally, 4 
over the past decade, it has become apparent that the resident intestinal microbiota also 5 
plays an important role in determining susceptibility to obesity [4-7]. This is partly due to the 6 
production of physiologically active metabolites during the process of microbial fermentation, 7 
which serve to harvest energy from dietary substrates that would otherwise be lost in the 8 
feces [8, 9]. This is typified by the fermentation of non-digestible carbohydrates, which, when 9 
supplemented into the diet, reduce appetite and body weight gain and improve glucose 10 
homeostasis in rodents and humans [10-12]. Key metabolites involved in transducing these 11 
beneficial metabolic effects are the short-chain fatty acids (SCFAs) acetate, propionate and 12 
butyrate [8]. Indeed, recent evidence suggests that the increased production of propionate 13 
following gastric bypass surgery for obesity is related to weight loss [13]. 14 
  15 
While SCFAs can be utilized for de novo synthesis of lipids and glucose [14] and serve as 16 
an energy source, they also act as signaling molecules at the recently de-orphaned G-17 
protein coupled receptors, free fatty acid receptor 2 (FFAR2, also known as GPR43) and 18 
FFAR3 (also known as GPR41) [15, 16]. Both receptors are expressed in various peripheral 19 
tissues, including the gastrointestinal tract, pancreas, bone marrow, spleen, thymus, lung, 20 
breast, and white adipose tissue; therefore, SCFAs may have widespread effects [15, 17-21 
20]. 22 
 23 
Within the gastrointestinal tract, FFAR2 and 3 have been localized to enteroendocrine L 24 
cells [17]. These specialized gut cells secrete the anorectic hormone peptide YY (PYY) and 25 
the incretin glucagon-like peptide-1 (GLP-1) in response to luminal nutrients, such as 26 
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sugars, amino acids, and long-chain fatty acids [17, 21, 22]. The highest density of L cells is 1 
found in the colon where these nutrients are unlikely to reach significant concentrations, but 2 
where SCFAs are most concentrated [23]. This suggests that gut hormone release may be 3 
an important host response to microbial fermentation and the consequent production of 4 
SCFAs. In support of this, acetate and propionate have been shown to stimulate the 5 
secretion of GLP-1 in vitro, an effect which was attenuated by FFAR2 deletion [24]. We 6 
therefore hypothesize that SCFA activation of L cell-expressed FFAR2, contributes to the 7 
effects of microbial fermentation on host metabolism. 8 
 9 
To determine if the beneficial metabolic effects of fermentable carbohydrate are mediated by 10 
FFAR2 signaling, we used mice with targeted deletion of this receptor. We demonstrate for 11 
the first time that this receptor is essential for mediating inulin’s ability to reduce food intake 12 
and protect against diet-induced obesity. FFAR2 signaling was found to drive an expansion 13 
of the PYY cell population within the colon, leading to increased circulating PYY, thus 14 
potentiating anorectic signaling by the gut. Our findings suggest that the fermentable 15 
carbohydrate stimulated expansion of PYY-expressing cells within the proximal colon is a 16 
physiologically important pathway linking diet, gut microbiota, and host metabolism. 17 
 18 
2. Methods and Materials 19 
2.1 Study approval 20 
All animal procedures were approved by the local ethical review process and the British 21 
Home Office Animals Scientific Procedures Act 1986 and carried out at Imperial College 22 
London (project license numbers: 70/7096, 70/7236 and 70/7595) or the Garvan Institute of 23 
Medical Research (12_22). 24 
 25 
2.2 Animals and diets:  26 
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Male Ffar2-/- C57BL/6 mice were obtained from Deltagen (http://wwww.deltagen.com). The 1 
Ffar2 gene was deleted by homologous recombination, which substitutes 55bp of Ffar2 exon 2 
1 with the β-gal-neo cassette, shifting the downstream amino acid sequence out of the 3 
reading frame [25]. Mice were maintained in cages under controlled temperature (21–23°C) 4 
and light (12 hours light/12 hours dark) with ad libitum access to food and water. Ffar2-/- and 5 
WT littermates at 9 weeks of age were fed a high-fat "Western" diet containing 21% 6 
anhydrous milk-fat and 34% sucrose, supplemented with 7.5% inulin (HFI) or an isocaloric 7 
control diet supplemented with 3.3% cellulose + 4.2% corn starch (HFC) for 14 or 2 weeks. 8 
For analysis of proliferation, Bromodeoxyuridine (2.6mM) was administered in the drinking 9 
water for the second week of the 2-week intervention. Investigators were blinded to the 10 
sample group allocation during the experiment and analysis. 11 
 12 
2.3 Magnetic resonance imaging:  13 
Adiposity was quantified by MRI following 13 weeks dietary intervention. Mice were 14 
anesthetized using 3% isoflurane in oxygen at a flow-rate of 2L/min and scans acquired on a 15 
4.7 Tesla Varian INOVA imaging system (Varian) using a quadrature birdcage coil [26].  16 
 17 
2.4 Intra-peritoneal glucose tolerance and insulin tolerance tests:  18 
Glucose and insulin tolerance tests were performed immediately prior to dietary intervention 19 
and following 11 and 12 weeks intervention, respectively.  For glucose tolerance tests Ffar2-20 
/-
 and WT C57BL/6 mice were fasted for 14h then injected intra-peritoneally (i.p.) with 2g/kg 21 
glucose. For insulin tolerance tests, mice were fasted for 5h then i.p. injected with 1IUkg-1 22 
insulin (Humulin 100IUml-1). Blood glucose measurements were taken via tail bleed using a 23 
glucometer (Bayer contour®).  24 
 25 
2.5 Energy expenditure and physical activity 26 
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Energy expenditure and physical activity were determined in 14-week old Ffar2-/- and WT 1 
C57BL/6 mice fed HFC or HFI diet for 4 weeks. Animals were transferred to individual cages 2 
in an open-circuit calorimeter (Oxymax Series; Columbus Instruments, Columbus, OH, 3 
USA). Temperature was maintained at 22°C, with airf low of 0.6L/min. Mice were 4 
acclimatized to the cages for 24 hours before beginning 24-hour recording of oxygen 5 
consumption (VO2) and carbon dioxide production (VCO2). Energy expenditure (kilocalories 6 
of heat produced) was calculated as calorific value (CV) x VO2, where CV = 3.815 + 1.232 x 7 
RER as previously published [27]. Physical activity was also measured, using an OPTO-M3 8 
sensor system (Columbus Instruments, Columbus, OH, USA), whereby ambulatory counts 9 
were a record of consecutive adjacent photo beam breaks in the horizontal space (X and Y 10 
axis). Data were presented as hourly averages for energy expenditure as well as hourly 11 
summation for ambulatory activities. The calorimeter was calibrated before each use using 12 
highly pure primary gas standards (O2 and CO2). 13 
 14 
2.6 Fecal mass and energy content 15 
Fecal matter was collected over four days. Energy content in the feces was determined in 16 
duplicate using a bomb calorimeter (PARR 1356; John Morris Scientific Pty Limited, 17 
Australia). Briefly, feces was compressed, pelleted (PARR Instrument Company; Moline, IL, 18 
USA), and weighed. Pellets were frozen and then freeze-dried (Telstar Cryodos -80°C 19 
freeze dryer, Progen Scientific, UK) for 24 hours. Each pellet was re-weighed to determine 20 
moisture content, placed in the bomb calorimeter for combustion, and energy content 21 
determined against a standard (benzoic acid).  22 
 23 
2.7 Quantitative enzymatic determination of glycerol  24 
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Quantitative enzymatic determination of glycerol was carried out using Free Glycerol 1 
Reagent (Sigma-Aldrich) following alkaline hydrolysis of triglycerides to glycerol and free 2 
fatty acids. Triplicate samples were diluted 1/5 and 10µl was used for analysis. 3 
 4 
 5 
2.8 Tissue collection 6 
Anesthetized mice were sacrificed by decapitation following a 4 hour fast. Blood was 7 
collected into heparinized syringes and transferred to tubes containing 15µl Trasylol (10,000 8 
KIUml-1) (Nordic Pharma) and 10µl dipeptidyl peptidase IV (DPP-IV) inhibitor KR-62436 9 
hydrate (2.7mM) (Sigma). Colonic tissue for immunohistochemistry was fixed in Bouin’s 10 
solution overnight at 4˚C and then paraffin embedded. Tissue samples for protein or 11 
triglyceride analysis were snap frozen in liquid nitrogen and stored at -80˚C. Samples for 12 
RNA analysis were stored in RNAlater™ (QIAGEN). 13 
 14 
2.9 Biochemical analyses 15 
LPS concentration in portal vein blood collected under terminal anesthesia was measured by 16 
using Endosafe-MCS (Charles River Laboratories) based on the Limulus amebocyte Lysate 17 
(LAL) kinetic chromogenic methodology as previously described [28]. 18 
 19 
2.10 DNA isolation from mouse colonic samples 20 
The colonic content of mice collected post mortem was stored at -80°C. Metagenomic DNA 21 
was extracted using a QIAamp-DNA stool mini-kit (Qiagen) according to manufacturer’s 22 
instructions. The primers and probes used to detect Total Bacteria, Bifidobacterium and 23 
Lactobacillus spp., were based on 16S rRNA gene sequences (Table 1) Detection was 24 
achieved with a STEP one PLUS instrument and software (Applied Biosystems) using 25 
MESA FAST qPCR MasterMix Plus for SYBR Assay (Eurogentec). Each assay was 26 
performed in duplicate in the same run. The cycle threshold of each sample was then 27 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
compared to a standard curve (performed in triplicate) made by diluting genomic DNA (five-1 
fold serial dilution) (BCCM/LMG and DSMZ). The data were expressed as Log bacteria/g of 2 
colonic content. 3 
 4 
2.11 Quantitative PCR 5 
Total RNA was isolated using TRI reagent (Sigma). Quantification and integrity analysis of 6 
total RNA was performed by running 1µl of each sample on an Agilent 2100 Bioanalyzer 7 
(Agilent RNA 6000 Nano Kit, Agilent). RNA was purified using an RNeasy Mini Kit (Qiagen) 8 
and reverse transcribed using a high-capacity cDNA reverse transcription kit (Life 9 
technologies). Gene expression of POMC, NPY, AgRP, Pax4, Pax6, Foxa1, and Foxa2 was 10 
quantified using 7900HT Fast Real-Time PCR System and TaqMan fluorogenic detection 11 
system (Applied Biosystems). Validated primers were purchased from Applied Biosystems. 12 
Comparative real-time PCR was performed in triplicate and data was analyzed according to 13 
the 2-∆CT method normalized to 18S.  14 
 15 
Real-time PCRs of ZO1 and Occludin were performed with the StepOnePlus real-time 16 
PCR system and software (Applied Biosystems) using Mesa Fast qPCR (Eurogentec) for 17 
detection according to the manufacturer’s instructions. RPL19 RNA was chosen as the 18 
housekeeping gene. All samples were run in duplicate and data were analyzed according to 19 
the 2-∆CT method. The identity and purity of the amplified product was checked through 20 
analysis of the melting curve carried out at the end of amplification. Primer sequences for the 21 
targeted mouse genes are presented as Supplementary Table S7. 22 
 23 
2.12 Organ culture 24 
Fresh perigonadal WAT and subcutaneous WAT fat pads (~100mg) were cultured in 1ml of 25 
RPMI serum free medium for 24h as previously described [29]. Cytokines secreted were 26 
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measured after 24h by specific TNF-α ELISA (DuoSet ELISA Development kit, R&D, and 1 
ELISA Ready-SET-Go, eBioscience). Data are shown as the concentration of cytokines 2 
secreted in 1ml of culture medium per gram of fat.  3 
 4 
2.13 Isolation of mononuclear cells and flow cytometry 5 
The stromal vascular fraction (SVF) containing mononuclear cells and pre-adipocytes was 6 
extracted from adipose tissue as previously described [29] and cells were stained with 7 
antibodies conjugated to fluorochromes, CD45 (30-F1), CD3 (145-2C11), CD4 (GK1.5), CD8 8 
(53-6.7), NKp46 (29A1.4), B220 (RA3-6B2), CD11b (M1/70), F4/80 (BM8) (eBiosciences). 7-9 
Amino-actinomycin D (eBiosciences) or LIVE/DEAD Fixable Dead Cell Stain (Invitrogen) 10 
were utilized to discriminate between live and dead cells. Samples were acquired using a 11 
LSRII cytometer (Becton Dickinson) and data were analyzed using FlowJo software (Tree 12 
Star). 13 
 14 
2.14 Quantification of gut hormone concentrations 15 
Peptides were extracted from colonic tissue in boiling 0.5molL-1 acetic acid for 15min. 16 
Colonic PYY, GLP-1, and substance P concentrations were determined using established in-17 
house radioimmunoassays [30]. The concentration of glucose-dependent insulinotropic 18 
polypeptide (GIP) was measured using a commercially available kit (Merck Millipore). Similar 19 
to colonic peptide levels, circulating and portal vein GLP-1 and PYY concentrations were 20 
determined using in-house radioimmunoassays. Circulating leptin was measured using a 21 
commercially available kit (Merck Millipore). 22 
 23 
2.15 Primary mixed colonic culture secretion experiments 24 
WT and Ffar2-/- mice aged 8-10 weeks were killed by CO2. Colons were collected and 25 
cleaned in ice-cold Leibovitz-15 medium (PAA). Tissue was digested with 0.4mgml-1 26 
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Collagenase-XI (Sigma) in high glucose Dulbecco's modified Eagle's medium (DMEM) (10% 1 
fetal calf serum, 100 Uml-1 penicillin, and 0.1mgml-1 streptomycin) at 37°C as previously 2 
described [31]. Cell suspensions were centrifuged (5min, 300×g) and the pellets re-3 
suspended in DMEM. Cell suspensions were filtered through a nylon mesh (pore size 4 
~250µm) and plated onto 24-well, 1% Matrigel–coated plates and incubated overnight at 5 
37oC in 95% O2 and 5% CO2. 6 
 7 
Secretion studies were performed 24h after culture preparation. Cultures were washed with 8 
secretion buffer (4.5mM KCl, 138mM NaCl, 4.2mM NaHCO3, 1.2mM NaH2PO4.2H2O, 2.6mM 9 
CaCl2, 1.2mM MgCl2, 10mM HEPES, 0.1% fatty acid-free BSA) and incubated with 50mM 10 
SCFA (acetate:propionate:butyrate 60:25:15) in secretion buffer for 2h at 37°C. 11 
Supernatants were collected and centrifuged. Cells were treated with lysis buffer containing: 12 
50mM Tris-HCl, 150mM NaCl, 1% IGEPAL-CA 630, 0.5% deoxycholic acid, and one tablet 13 
of complete EDTA-free protease inhibitor cocktail (Roche). PYY and GLP-1 were assayed in 14 
supernatants and cell extracts by radioimmunoassay as previously described [32, 33]. 15 
Hormone secretion was expressed as a fraction of the total of that hormone. 16 
 17 
2.16 Immunofluorescence and microscopy  18 
7µm wax embedded sections were stained for PYY using primary polyclonal rabbit anti-PYY 19 
(1:1000, Abcam, ab22663), with secondary FITC-conjugated chicken anti-rabbit antibody 20 
(1:200, Abcam, ab6825). Staining for GLP-1 was carried out using primary polyclonal mouse 21 
anti-GLP-1 with secondary TRITC-conjugated goat anti-mouse (1:200, Abcam, ab5867). 22 
BrdU was stained for using primary monoclonal mouse anti-BrdU (1:100, Sigma, 23 
13843420001) with secondary TRITC-conjugated polyclonal goat F(Ab) anti-mouse (1:200). 24 
5HT was stained for using primary goat anti-5HT (1:500 Abcam, ab66047) with polyclonal 25 
donkey anti-goat (1:50, Abcam, ab6566). Nuclei were stained with DAPI (4’,6-diamidino-2-26 
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phenylindole) in Fluroshield (Abcam). Immunofluorescent images were acquired on a Carl 1 
Zeiss Axiovert 100S TV microscope.  The operator performing the cell-counting was blinded 2 
to the groupings. 3 
 4 
2.17 PYY-GFP organoid culture and treatments 5 
Mouse intestinal crypts from transgenic PYY-GFP mice (a kind gift from Prof. Rodger Liddle, 6 
Duke University) [34] were isolated, cultured, and grown into organoids as described 7 
previously [35]. Crypts were cultured in advanced Dulbecco’s modified Eagle’s medium/F12 8 
containing 100 units/mL penicillin/streptomycin, 10mM HEPES, 2mM Glutamax, 9 
supplements N2 (1x) and B27 (1x), and 50 ng/mL mouse epidermal growth factor (all from 10 
Life Technologies); and 1mM N-acetylcysteine (Sigma-Aldrich) and mouse Noggin and 11 
mouse R-spondin-1, both as 10% conditioned medium. Medium was changed every 2 days. 12 
On day 2 after splitting, either 10µM CFMB or 10µM AR420626 was added to the medium. 13 
For control mouse organoids, regular medium without CFMB or AR420626 was used. 14 
Organoids were imaged on day 6, after 96 hours of treatment, using a Nikon Inverted 15 
Spinning Disk confocal equipped with a humidified, temperature control environmental 16 
chamber. Images were obtained using NIS Elements AR software. To count the number of 17 
PYY positive cells in each organoid we obtained a continuous z-dimension stack (step size: 18 
5µM).  19 
 20 
2.18 Wholemount  Immunostaining of organoids 21 
 22 
Organoids were isolated from Matrigel, rinsed in PBS, and fixed in 4% PFA.  After 23 
permeabilization for 30 min, organoids were blocked with 3% BSA. Organoids were 24 
incubated overnight with a primary antibody against GLP-1 (Abcam).  Alexa Fluor 568 25 
donkey anti-mouse (Jackson Laboratories) was used as secondary antibody. To count the 26 
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number of GLP-1 positive cells in each organoid, we obtained a continuous z-dimension 1 
stack (step size: 5µM) using a Nikon Inverted Spinning Disk confocal. 2 
 3 
2.19 Statistics:  4 
Data are presented as the mean ± SEM. Most of the experiments were evaluated by a two-5 
way ANOVA. A generalized estimating equation was applied for analysis of food intake and 6 
body weight. Comparisons were considered statistically significant when P was less than 7 
0.05. 8 
 9 
 10 
3. Results 11 
3.1 FFAR2 is required for the beneficial effects of fermentable carbohydrate 12 
supplementation on body weight. 13 
Inulin supplementation protects against body weight gain in humans and animals [10-12]. 14 
We hypothesized that this is due to FFAR2 activation by SCFAs following microbial 15 
fermentation. To investigate the contribution of FFAR2, Ffar2-/- mice and WT littermates 16 
were fed a HFD supplemented with inulin or a non-fermentable isocaloric control diet for 14 17 
weeks. We have previously found that this diet results in a doubling of colonic SCFA 18 
concentration following 8 weeks supplementation in mice with the same genetic background 19 
[26].  20 
 21 
Body weight was not affected by genotype at age 8-10 weeks when mice were fed standard 22 
chow (WT: 24.89 ± 0.34g, Ffar2-/-: 25.70 ± 0.42g) (Supplementary Figure 1a).  However, 23 
inulin supplementation exerted a protective effect against diet-induced obesity over the 24 
following 14 weeks, dependent on FFAR2 expression (percentage body weight change: WT 25 
HFC: 33.88 ± 2.83%, WT HFI: 20.38 ± 1.25%; Ffar2-/- HFC: 30.49 ± 2.38%, Ffar2-/- HFI: 26 
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30.67 ± 3.65%, p<0.001) (Figure 1a). MRI analysis revealed that differences in body weight 1 
were due to decreased adiposity (p<0.05) (Figure 1b). As expected, inulin supplementation 2 
also reduced liver triglyceride (p<0.05) and leptin concentrations (p<0.05) in WT mice, 3 
corresponding to lower fat mass (Figure 1c-d). Taken together, these data demonstrate that 4 
the ability of inulin to prevent weight gain in response to HFD is FFAR2-dependent. 5 
 6 
The reduction in body weight observed in WT mice supplemented with inulin was associated 7 
with decreased food intake (WT HFC: 190.1 ± 5.9g; WT HFI: 181.9 ± 5.7g, Ffar2-/- HFC: 8 
190.5 ± 3.7g, Ffar2-/- HFI: 193.6 ± 4.3g (p<0.05)) (Figure 1e). As appetite is regulated via 9 
appetite-inhibiting (anorexigenic) pro-opiomelanocortin (POMC) neurons and appetite-10 
stimulating (orexigenic) neuropeptide Y (NPY) and agouti-related peptide (AgRP) co-11 
expressing neurons within the hypothalamic arcuate nucleus, we measured gene expression 12 
of these neuropeptides. Expression of all three hypothalamic neuropeptides has previously 13 
been demonstrated to be sensitive to nutritional status, such that orexigenic neuropeptides 14 
Npy and Agrp are elevated following fasting [36, 37], while anorexigenic neuropeptide Pomc 15 
expression is reduced [38]. As such gene expression of these neuropeptides serves as an 16 
indicator of anorectic drive. While we found that inulin supplementation did not alter Pomc or 17 
Npy expression (Figure 1f-g), Agrp expression was decreased in WT but not Ffar2-/- mice 18 
(p<0.05) (Figure 1h), suggesting that inulin acts via FFAR2 to decrease hypothalamic 19 
orexigenic drive.  20 
 21 
Body weight is not only a function of food intake, it is also governed by energy absorption 22 
and expenditure. To determine whether the reduction in body weight was associated with 23 
alterations in energy expenditure, we measured locomotor activity and basal metabolic rate, 24 
both of which were unaffected by diet or genotype (Figure 1i-j). As energy expenditure is 25 
influenced by brown adipose tissue thermogenesis, gene expression of the thermogenic 26 
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protein Ucp1 was measured. In agreement with recently published data, gene expression of 1 
Ucp1 was unchanged following inulin supplementation (Figure 1k) [39]. To assess energy 2 
absorption, fecal energy content was measured. Inulin supplementation modestly reduced 3 
fecal energy loss in WT and Ffar2-/- mice (p<0.05) (Figure 1l). Collectively, these data 4 
demonstrate the effect of inulin on body weight was not due to increased energy expenditure 5 
or fecal energy loss but was likely a result of the decrease in food intake.  6 
 7 
3.2 Glucose homeostasis improvement following fermentable carbohydrate 8 
supplementation is dependent on FFAR2. 9 
Fermentable carbohydrate consumption has previously been shown to be associated with 10 
an improvement in glucose homeostasis [11]. Prior to dietary intervention, all groups were 11 
equally glucose tolerant and insulin sensitive (Supplementary Figure 2). After 13 weeks, WT 12 
mice given inulin exhibited improved glucose tolerance (p<0.05). However, insulin tolerance 13 
was unchanged (Supplementary Figure 2). Interestingly, inulin lowered fasted glucose levels 14 
in WT and Ffar2-/- mice via a non-FFAR2 mediated mechanism (p<0.01) (Supplementary 15 
Figure 2). 16 
 17 
3.3 Deletion of FFAR2 does not alter the microbial density of Bifidobacterium spp., 18 
Lactobacillus spp., or total bacteria within the colon. 19 
Colonic microbial density and species composition influence inulin fermentation and SCFA 20 
production. Therefore, it was possible that FFAR2 could drive alterations in microbial 21 
diversity and account for the metabolic benefits we observed. To address this, we carried 22 
out targeted enquiry of bacterial species that are important for inulin fermentation and that 23 
are increased by fermentable carbohydrate supplementation. Total bacterial numbers were 24 
increased by inulin supplementation (p<0.001), consistent with previous studies [40]. 25 
Additionally, species belonging to the Bifidobacterium spp., which play a key role in 26 
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fermenting inulin, were also increased (p<0.05), while the abundance of Lactobacillus spp. 1 
was unaltered. Importantly, there were no effects of genotype on microbial number or 2 
species-specific density (Figure 2); hence, the FFAR2-dependent effects of inulin on body 3 
weight are not driven by alterations in bacterial cell density.  4 
 5 
3.4 Improvements in glucose homeostasis were not associated with adipose tissue 6 
immune cell infiltration. 7 
Obesity-associated inflammation impairs glucose homeostasis. As FFAR2 is involved in 8 
immune cell chemotaxis [41], we examined the white adipose tissue (WAT) immune cell 9 
phenotype (Supplementary Figure 3). FFAR2 deletion reduced the infiltration of 10 
subcutaneous WAT immune cells (CD45+) and visceral WAT macrophages (CD11b+ F4/80+) 11 
as previously described [42] (p<0.05). Inulin supplementation reduced CD4+ T-cell infiltration 12 
in subcutaneous WAT of WT mice in association with improved glucose homeostasis 13 
(Supplementary Figure 2d) (p<0.01). However, it is unlikely that reduced CD4+ T-cell 14 
infiltration directly influenced glucose homeostasis as immune cell populations were also 15 
decreased by Ffar2 deletion, which was not associated with such improvements. 16 
Conversely, one observation, which could account for improved glucose homeostasis, was 17 
that spontaneous TNF-α release from visceral WAT decreased following inulin 18 
supplementation in WT animals (p<0.01) (Supplementary Figure 3j).  19 
 20 
3.5 Improvements in glucose homeostasis were not associated with alterations in 21 
markers of intestinal barrier function. 22 
Systemic inflammation is also influenced by intestinal leakage of pro-inflammatory 23 
lipopolysaccharide (LPS). As microbiota influence intestinal barrier function [43], we 24 
measured gene expression of intestinal tight junction proteins as a marker of barrier 25 
integrity. Inulin supplementation caused a trend towards an increase in gene expression of 26 
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tight junction proteins ZO-1 and Occludin independently of genotype (Supplementary Figure 1 
4a-c). Portal vein LPS was also measured as an indicator of barrier function. Inulin did not 2 
influence circulating LPS concentrations, indicating that alterations in intestinal barrier 3 
function are also unlikely to contribute to the observed metabolic improvements 4 
(Supplementary Figure 4d). 5 
 6 
3.6 Fermentable carbohydrate supplementation stimulates FFAR2-dependent release 7 
of PYY.  8 
Increased PYY and GLP-1 secretion has been implicated in mediating the effects of 9 
fermentable carbohydrate on body composition and glucose homeostasis [44, 45]. To 10 
investigate whether changes in body weight were associated with release of these 11 
hormones, we measured portal vein PYY and GLP-1 concentrations following 2 weeks 12 
dietary intervention before significant differences in body weight between groups are 13 
apparent. Inulin supplementation significantly increased circulating PYY in WT (p<0.05) but 14 
not in Ffar2-/- mice (p=0.39) (WT HFC: 54.7 ± 17.0pmol.L-1, WT HFI: 84.9 ± 19.3 pmol.L-1, 15 
Ffar2-/- HFC: 52.8 ± 22.2 pmol.L-1, Ffar2-/- HFI: 66.91 ± 28.4 pmol.L-1) (Figure 3a). The ability 16 
of inulin to increase portal vein PYY appears to be reduced and not completely abolished by 17 
FFAR2 deletion, as the difference between WT HFI and Ffar2-/- HFI groups was not 18 
significant. In contrast to PYY, GLP-1 release was increased independently of FFAR2 19 
following inulin supplementation (WT: p<0.05, Ffar2-/-: 0.0548) (Figure 3b), demonstrating 20 
that inulin differentially regulates PYY and GLP-1 secretion via FFAR2-dependent and 21 
independent mechanisms respectively.  22 
 23 
While SCFAs are implicated in mediating the effects of inulin due to the selectivity of FFAR2 24 
for these metabolites, we confirmed their role in a primary colonic cell model [31]. Exposure 25 
to mixed SCFAs, in the same ratio as found in the gut following inulin fermentation [46], 26 
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increased secretion of PYY by 127% (p<0.0001)  and GLP-1 by 54% (p<0.001) compared to 1 
baseline. This effect was not observed in Ffar2-/- tissue (PYY: p=0.07, GLP-1: p=0.42), 2 
indicating SCFAs act via FFAR2 to stimulate both PYY and GLP-1 secretion (Figure 3c-d). 3 
These findings are similar to the results of Tolhurst et al., who demonstrated FFAR2-4 
dependent GLP-1 release in response to mixed SCFAs [24]. The dependence of SCFA-5 
induced GLP-1 secretion on FFAR2 expression is contrary to the receptor-independent 6 
effects observed in vivo. This may be due to SCFAs acting via different acute vs. chronic 7 
mechanisms. Alternatively, other fermentation products present in vivo could influence GLP-8 
1 secretion.  9 
 10 
3.7 Fermentable carbohydrate acts via FFAR2 to specifically increase colonic PYY.  11 
Increased concentrations of circulating PYY and GLP-1 following inulin supplementation 12 
may reflect an increased capacity of the gut to secrete these hormones due to increased 13 
colonic hormone content. To address this, we measured colonic PYY and GLP-1 14 
concentrations. Following inulin supplementation, colonic PYY was increased by 130%, 15 
(p<0.05) an effect that was abolished in Ffar2-/- animals (p=0.65) (Figure 3e). In contrast, 16 
inulin significantly increased colonic GLP-1 regardless of genotype and thus was not 17 
receptor dependent (WT: p<0.01, Ffar2-/-: p<0.01) (Figure 3f). These effects were specific to 18 
L cells as hormones expressed in developmentally distinct enteroendocrine cell types such 19 
as GIP and Substance P were unchanged. Crypt length as well as goblet and 20 
enterochromaffin cell densities were also unaffected (Supplementary Figure 5). Colonic PYY 21 
and GLP-1 concentrations reflected the circulating concentrations, indicating that inulin 22 
increases gut hormone release by increasing the amount of PYY and GLP-1 within the 23 
colon. 24 
 25 
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3.8 Fermentable carbohydrate supplementation increases PYY cell density in the 1 
proximal colon via FFAR2. 2 
To determine whether the increased colonic PYY and GLP-1 concentrations were due to an 3 
increase in L cell density, we used immunofluorescent staining to quantify PYY- and GLP-1-4 
expressing cells. Body weight at the time of tissue collection was not significantly different 5 
between groups (2 weeks on inulin supplemented diet) (Supplementary Figure 6). In WT 6 
mice, inulin supplementation caused an 87% increase in PYY (p<0.05) and 73% increase in 7 
GLP-1 cell density (p<0.05). Whereas, in Ffar2-/- mice, GLP-1 cell density was increased by 8 
60% (p<0.05), and PYY cell-density was unchanged (p=0.23) (Figure 4). While the 9 
expansion of the PYY-expressing cell population is dependent on FFAR2, the expansion of 10 
the GLP-1-expressing cell population occurs independently of FFAR2. We also observed an 11 
increase in the density of cells that co-express both hormones (Figure 4c). Therefore, the 12 
increase in GLP-1 cell density appears to be due to GLP-1 being expressed in cells that 13 
would otherwise have been PYY singly labeled cells. Conversely, the increase in PYY cell 14 
density was due to an expansion of L cells that did not express GLP-1. These data 15 
demonstrate that inulin increases colonic gut hormone concentrations by increasing the 16 
density of specific enteroendocrine cell types in the colon. 17 
 18 
To assess whether increased PYY cell density was due to an increase in the rate of PYY cell 19 
formation, bromodeoxyuridine (BrdU) was administered to mice for the second week of a 2-20 
week intervention. BrdU incorporates into the DNA of dividing cells, allowing identification of 21 
newly formed cells. PYY-expressing cells, which stained positive for BrdU, were 129% more 22 
abundant in WT (p=0.0003) but not Ffar2-/- mice (p=0.53) following inulin supplementation 23 
(Figure 4d), confirming that inulin promotes formation of new PYY cells in a FFAR2-24 
dependent manner.      25 
 26 
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In rodents, the intestinal epithelium is replaced every 4-5 days [47]. Newly formed colonic 1 
cells are generated from multipotent stem cells through progressive restrictions in 2 
developmental potential. The fate of a cell is the result of the expression of specific 3 
transcription factors, which orchestrate intricate differentiation pathways by regulating the 4 
transcription of various genes. While it is currently unclear which factors direct expression of 5 
each specific gut hormone, transcription factors known to function in terminal differentiation 6 
of GLP-1 and PYY cells include Pax4, Pax6, Foxa1, and Foxa2 [48-51]. To further elucidate 7 
the mechanism by which inulin regulates the expansion of PYY cells, we measured gene 8 
expression of these transcription factors. While Pax6, Foxa1 and Foxa2 were unaltered 9 
following inulin feeding, Pax4 was significantly and receptor-dependently increased (WT: 10 
p=0.017, Ffar2-/-: p=0.69) (Figure 5). This suggests that Pax4 may link FFAR2 activation to 11 
the expansion of the PYY cell population.  12 
 13 
3.9 FFAR2 but not FFAR3 activation increases PYY cell density in vitro. 14 
To determine the relative roles of FFAR2 and FFAR3 on PYY and GLP-1 cell density, we 15 
used selective agonists for FFAR2 (CFMB) [52] and FFAR3 (AR420626) [35] in an in vitro 16 
organoid culture. The doses of each agonist were chosen based on previous reports in the 17 
literature and because they did not result in cellular toxicity in our organoid model. Tollhurst 18 
et al. demonstrate that a dose of 30µM of CFMB increases calcium flux in isolated colonic 19 
cultures [45]. Whilst Nohr et al. [46] used doses of 10µM and 30µM of both agonists based 20 
on their potencies. CFMB is reported to have an IC50 of 4.7µM at FFAR2 but displays no 21 
activity at FFAR3 up to 1mM, while AR420626 is reported to have an IC50 value of 117nM for 22 
FFAR3 and does not activate FFAR2 at concentrations up to 100µM in cAMP accumulation 23 
assays [52].  24 
 25 
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Primary intestinal crypts from PYY-GFP mice were cultured in a three-dimensional, growth-1 
factor rich environment, recapitulating in vivo colonic multi-lineage differentiation [35, 53]. 2 
Exposure of colonic organoids to FFAR2 agonist CFMB led to increased PYY, but not GLP-1 3 
cell density (p<0.001) (Figure 6). In contrast, the FFAR3 agonist had no effect on PYY or 4 
GLP-1 cell density. It therefore appears that SCFAs act via FFAR2 but not FFAR3 to 5 
increase PYY cell density.  6 
 7 
4. Discussion 8 
The discovery that gut microbiota influences physiology and, in certain circumstances, may 9 
cause disease pathologies has led to an intensive research effort to unravel microbiota-host 10 
interactions. Understanding the effects of microbial fermentation on host metabolism has 11 
been of particular interest, because consumption of fermentable carbohydrate reduces 12 
appetite and prevents body weight gain [10-12, 20]. Evidence points to the production of 13 
SCFAs by the gut microbiota as an important appetite regulatory signal. In this study, we 14 
report for the first time that FFAR2 expression is essential for inulin to exert these beneficial 15 
effects. As such, targeting this pathway in man could be a viable means of preventing 16 
obesity. 17 
 18 
Our key finding is that fermentable carbohydrate drives an increase in PYY-cell density 19 
within the colon, which is mediated via FFAR2 and results in increased circulating PYY 20 
concentrations. This is associated with a reduction in food intake and protection against diet-21 
induced obesity. Furthermore, FFAR2 but not FFAR3 activation at the level of the intestinal 22 
epithelium is sufficient to increase PYY cell density in isolated organoids. We also 23 
demonstrate that inulin, acting via FFAR2, stimulates the expression of Pax4, a transcription 24 
factor that has previously been shown to be essential for differentiation of PYY cells in the 25 
fetal mouse colon [54]. We therefore propose that inulin, following microbial fermentation to 26 
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SCFAs, acts via FFAR2 to influence cellular differentiation pathways and promote PYY cell 1 
fate. Increasing the density of PYY cells provides the colon with a greater potential for 2 
release of PYY, which is known to reduce food intake.  3 
A number of interesting questions remain to be answered. As FFAR2 activation drives 4 
changes in enteroendocrine cell fate, is it expressed by progenitor cells, either by epithelial 5 
LgR5+ stem cells or by endocrine NGN3+ progenitors, or does FFAR2 act later in the 6 
enteroendocrine development pathway? Lineage tracing experiments could allow the 7 
determination of the origin of newly generated PYY singly labelled cells. Furthermore, it will 8 
be important in the future to determine the intracellular pathways triggered by FFAR2 9 
activation that lead to altered endocrine cell fate. Understanding these processes could 10 
identify targets for manipulation of endocrine cell fate in order to treat disease.  11 
 12 
While we describe an important role for FFAR2 in driving increased PYY secretion, FFAR2 13 
signaling has previously been reported to influence food intake and body weight via the 14 
inhibition of ghrelin secretion [52] and the suppression of insulin signaling in adipocytes [55]. 15 
As such, it is likely that SCFAs exert their effects on metabolism via multiple complementary 16 
pathways. However, fermentation occurs primarily in the colon where there is a high density 17 
of L cells, suggesting that the mechanism described here plays a critical role in transducing 18 
the effects of SCFAs on appetite.  19 
 20 
The luminal concentrations of SCFAs within the colon have been estimated to be 70-21 
130mmol [56]. This exceeds the concentration range to which FFAR2 is sensitive and would 22 
suggest that colonic FFAR2 is constantly active. However, due to a number of factors, it is 23 
unlikely that FFA receptors are exposed to these concentrations. Firstly, in the colon, the 24 
microbiota are compartmentalized to the outer mucus layer; the inner mucus layer contains 25 
almost no microbiota and serves to protect the epithelium. Therefore, there is a separation 26 
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between the bacteria and the epithelium, through which a concentration gradient would form. 1 
In the distal colon, the ~50 µm inner mucus layer has been shown to be replaced every hour 2 
[57]. Secondly, the crypt opening is narrow, creating further impediment to the diffusion of 3 
SCFAs. Finally, SCFAs are rapidly absorbed by the epithelial cells, thereby depleting the 4 
concentration of SCFAs in the immediate environment. The precise concentration of the 5 
different SCFAs at the level of the colonic epithelium is not known. However, based on the 6 
EC50 values of SCFAs for FFAR2 one might imagine that the local SCFA concentration 7 
would be in the micromolar range [15]. 8 
 9 
Additionally, there are likely to be non-receptor mediated actions of SCFAs following dietary 10 
fermentable carbohydrate supplementation. Recently, it has been demonstrated that acetate 11 
alters hypothalamic neuronal activity [58]. However, the central actions of SCFAs on food 12 
intake, to date, have only been observed acutely following intracerebroventricular 13 
administration [58]. In contrast, our data describe long-term FFAR2-dependent adaptations, 14 
which may underlie the ability of fermentable carbohydrates to exert sustained reductions in 15 
body weight. SCFA also have been reported to act via a non-receptor mediated mechanism 16 
within the liver and adipose tissue to reduce peroxisome proliferator-activated receptor 17 
gamma (PPAR-γ) expression, thereby preventing body weight gain and improving insulin 18 
sensitivity [59].  These observations are described following dietary supplementation with 19 
SCFAs as opposed to fermentable carbohydrate. In contrast to the microbiota-dependant 20 
production of SCFAs from fermentable carbohydrate, dietary SCFAs can be absorbed earlier 21 
in the gastrointestinal tract, and therefore colonic mechanisms would be largely evaded. 22 
Collectively, the accumulating data within this field reveal a complex system of intertwined 23 
receptor- and non-receptor mediated mechanisms that act together to prevent body weight 24 
gain.  25 
 26 
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In agreement with previous studies, we also find that fermentable carbohydrate increased 1 
GLP-1 secretion [44, 45]. This could explain the decreased fasted plasma glucose observed 2 
with inulin supplementation due to the insulinotropic effects of GLP-1 [60].  In support of this, 3 
it has recently been demonstrated that dibenzapine administration, which blocks the Notch 4 
signaling pathway, increases intestinal GLP-1 cell numbers in a HFD model of impaired 5 
glucose tolerance and improves insulin responses to glucose and glucose tolerance [61]. 6 
Alternatively, recently published data suggest that the improvements in glucose homeostasis 7 
could be associated with FFAR3-dependant alterations in intestinal gluconeogenesis [62, 8 
63]. Propionate signals via FFAR3 expressed on periportal afferent neurons and via a gut-9 
brain neural circuit to induce intestinal gluconeogenesis, which results in improved glucose 10 
homeostasis [63]. 11 
 12 
Similar to the increase in PYY, the increase in circulating GLP-1 was associated with a 13 
greater cell density. Previously Cani et al. have demonstrated that fermentable carbohydrate 14 
increases colonic GLP-1 cell density in association with increased expression of the 15 
transcription factor Neurogenin3 (NGN3) [44, 64]. NGN3 acts upstream of Pax4, Pax6, 16 
Foxa1, and Foxa2 and is responsible for determining an enteroendocrine cell fate. This 17 
suggests that fermentable carbohydrate increases production of new enteroendocrine cells. 18 
However, the observed increase in GLP-1 cell density was not associated with alterations in 19 
Pax4, Pax6, Foxa1, and Foxa2 expression, indicating that these transcription factors are not 20 
responsible for driving increases in GLP-1 cell density in response to inulin. 21 
 22 
Contrary to the increase in PYY cell density, the increase in GLP-1 cell density occurred 23 
independently of FFAR2. In agreement with a number of other studies, we found only partial 24 
co-localization of PYY and GLP-1 [23, 65-69], despite the prevailing view that GLP-1 and 25 
PYY are co-expressed in L cells and co-stored in secretory vesicles. This may be because 26 
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the degree of co-localization varies depending on location along the proximal-distal axis, 1 
between species, with metabolic state, and between studies [66, 67]. It is therefore of great 2 
interest to identify factors that differentially modulate the expression of these two gut 3 
hormones.  4 
 5 
The mechanism underlying the increase in GLP-1 cell density does not appear to be FFAR3 6 
activation, as FFAR3 agonism did not alter the density of GLP-1 cells in organoids. 7 
Furthermore, Ffar2 deletion has previously been shown to prevent SCFA-induced GLP-1 8 
release in vitro to a greater degree than FFAR3 deletion [24],  suggesting that FFAR3 may 9 
be less important in mediating SCFA signaling in L cells. One possibility is that SCFAs cross 10 
the cell membrane via non-ionic diffusion and may act intracellularly to increase GLP-1 cell 11 
density [70]. However, such a mechanism perhaps would be associated with a more 12 
generalized proliferative effect compared to the very specific effects that we observed. 13 
Finally, and more plausibly, additional bioactive fermentation products may stimulate an 14 
expansion of the GLP-1 cell population. Undoubtedly, elucidation of this mechanism will be 15 
an important discovery that could improve treatment options for diabetes. 16 
 17 
5. Conclusion 18 
We have demonstrated that FFAR2 is pivotal for transducing the beneficial metabolic effects 19 
of fermentable carbohydrate. By stimulating microbial SCFA production using inulin, we 20 
demonstrate that these fermentation products act via FFAR2 to drive an expansion of the 21 
PYY cell population within the proximal colon. The resulting increase in cell density leads to 22 
increased circulating PYY, which previously has been shown to reduce appetite [71]. This 23 
presents a new understanding of gut physiology whereby the gut exhibits cellular plasticity, 24 
allowing it to respond to alterations in dietary composition. Such changes alter the capacity 25 
for anorectic signaling (Figure 7). This paradigm likely represents a more general 26 
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physiological mechanism and, if true, begs the question as to whether other nutrients or 1 
microbial metabolites influence enteroendocrine plasticity in order to alter host physiology. 2 
By targeting this pathway with drugs or nutraceuticals, it may be possible to prime the colon 3 
to produce a greater anorectic signal in response to nutrients to treat or prevent obesity.  4 
 5 
 6 
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 37 
Figure legends:  38 
Figure 1: The effect of fermentable carbohydrate supplementation on metabolic parameters in 39 
high-fat fed WT and Ffar2-/- mice. Percentage body weight change (n=19-22) (a), food intake (b), 40 
energy expenditure (c), activity (d), subcutaneous adiposity at 11 weeks (e), hepatic triglyceride (f), 41 
plasma leptin (g), fecal energy loss (h), hypothalamic expression of Agrp (i), Npy (j), Pomc (k), and 42 
scapular brown adipose tissue Ucp1 expression (l) for male Ffar2-/- and WT littermate C57BL/6 mice 43 
fed a high-fat diet supplemented with inulin (HFI) or cellulose (HFC)(control) n=10-12 over a 14 week 44 
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period. Data represent mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001. Statistical differences 1 
determined by GEE (a-b) or two-way ANOVA with post-hoc bonferonni comparisons (c-h). 2 
 3 
Figure 2. The effect of fermentable carbohydrate supplementation on bacterial density or 4 
species composition in high-fat fed WT and Ffar2-/- mice. Total bacteria (a), Bifidobacteria spp. 5 
(b), Lactobacillus spp. (c), for male Ffar2-/- and WT littermates fed a high-fat diet supplemented with 6 
inulin (HFI) or cellulose (HFC)(control) n=10-12 over a 10 week period. Data represent mean ± S.E.M. 7 
*p<0.05, ***p<0.001. Statistical differences determined by two-way ANOVA with post-hoc bonferonni 8 
comparisons.  9 
 10 
Figure 3: Gut hormone concentration following fermentable carbohydrate supplementation or 11 
incubation with SCFA in WT and Ffar2-/- mice. Portal vein peptide YY (PYY) (a), portal vein 12 
Glucagon-like peptide-1 (GLP-1) (b), colonic PYY (c), and colonic GLP-1 (d) concentrations of male 13 
Ffar2-/- and WT littermates fed a high-fat diet supplemented with inulin (HFI) or cellulose (HFC) for 14 14 
weeks (a-b, n=10-12) or 2 weeks (c-d n=4-6). Percentage PYY (e) of GLP-1 (f) release from mixed 15 
colonic cultures taken from Ffar2-/- and WT littermates controls following incubation with 50mM SCFA 16 
(30mM acetate, 12.5mM propionate, 7.5mM butyrate) (e). Data represent mean ± S.E.M. *p<0.05, 17 
**p<0.01, ***p<0.001. Statistical differences determined by students t-test or two-way ANOVA with 18 
post-hoc bonferonni comparisons. 19 
 20 
Figure 4: The effect of fermentable carbohydrate supplementation on L cell density in high-fat 21 
fed WT and Ffar2-/- mice. PYY (a), GLP-1 (b), GLP-1/ PYY co-localized cells per mm2 (c) and the 22 
percentage of PYY+ cells which also stained positive for BrdU (d) within the proximal colon of male 23 
Ffar2-/- and WT littermates fed a high-fat diet supplemented with inulin (HFI) or cellulose (HFC) for 2 24 
weeks (n=4-6). Representative images of PYY and GLP-1 staining are shown in e, f, g, and h. 25 
Representative images of PYY and BrdU staining are shown in i and j. Scale bars are equal to 26 
100µm. Data represent mean ± S.E.M. *p<0.05, ***p<0.001. Statistical differences determined by two-27 
way ANOVA with post-hoc bonferonni comparisons. 28 
 29 
Figure 5: The effect of fermentable carbohydrate on colonic transcription factor expression in 30 
vivo. Gene expression relative to 18S was determined for Pax4 (a) Pax6 (b), Foxa1 (c), and Foxa2 31 
(d) in the colon of male Ffar2-/- and WT littermates fed a high-fat diet supplemented with inulin (HFI) or 32 
cellulose (HFC) for 2 weeks, n=6-8. Data represent mean ± S.E.M. *p<0.05. Statistical differences 33 
determined by two-way ANOVA with post-hoc bonferonni comparisons. 34 
 35 
Figure 6: Effect of CFMB and AR420626 on PYY and GLP-1 cell fate in intestinal organoids. 36 
Organoids from PYY-GFP mice were cultured in absence (a, d) or presence of 10µM CFMB (b) and 37 
f 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
31 
 
10µM AR420626 (e) for 96 hours. Shown are Z-stack projections covering the whole organoid. Scale 1 
bars: 100µm. (c, f) PYY cell numbers after 96 hour continuous exposure with 10µM CFMB (c) and 2 
10µM AR420626 (f). n=30-60 organoids (2 platings). Number of GLP-1 +ve cells in organoids from 3 
PYY-GFP mice after 96-hour exposure to CFMB (g) and AR420626 (h). n=100-300 organoids (3 4 
platings). Expression of Pyy (i) and Gcg (j) following 96-hour exposure to CFMB in WT and Ffar2-/- 5 
organoids. All data are presented as mean ± S.E.M, ****p<0.0001, ***p<0.001. *p<0.05. Statistical 6 
differences determined by nonpaired 2-tailed Student’s t test (c, f, g, h) or 2-way ANOVA (i-j). 7 
 8 
Figure 7: Mechanism by which fermentable carbohydrate prevents body weight gain. Following 9 
consumption, fermentable carbohydrate (FCH) is fermented by gut microbiota to produce short chain 10 
fatty acids (SCFAs). SCFAs subsequently act at free fatty acid receptor 2 (FFAR2) within the colon to 11 
enhance PYY cell density, thereby augmenting the capacity of the gut to release PYY. PYY acts to 12 
reduce orexigenic drive via AgRP neurons within the arcuate nucleus and reduce food intake.  13 
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Highlights: 
 
1. Fermentable carbohydrate protects against diet-induced obesity via FFAR2 
2.  Fermentable carbohydrate increases GLP-1 cell density independently of FFAR2 
3. FFAR2 signalling increases PYY cell density and circulating PYY concentration 
